19996208	207	Davies MA	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.	Clinical cancer research 	2009	62
24382882	217	Chen CH	Targeting aldehyde dehydrogenase 2: new therapeutic opportunities.	Physiological reviews	2014	51
23598171	238	Mossé YP	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.	The Lancet. Oncology	2013	100
24819116	238	Johnson TW	Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo4,3-h2,5,11-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.	Journal of medicinal chemistry	2014	38
26698910	238	Shaw AT	Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.	The New England journal of medicine	2016	42
24508103	673	McArthur GA	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.	The Lancet. Oncology	2014	119
24582505	673	Larkin J	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.	The Lancet. Oncology	2014	28
24737664	673	Yaeger R	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.	Cancer	2014	29
24768112	673	Brose MS	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.	Lancet	2014	112
24958825	673	Hu-Lieskovan S	Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.	Journal of clinical oncology 	2014	41
21412932	1019	Birnbaum DJ	Genome profiling of pancreatic adenocarcinoma.	Genes, chromosomes and cancer	2011	43
24100703	1026	Sanli T	AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway.	Cancer biology and therapy	2014	37
16799619	1029	Laurent-Puig P	Genetics of hepatocellular tumors.	Oncogene	2006	82
25009010	1029	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	47
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
25822088	1029	Schulze K	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.	Nature genetics	2015	104
26099527	1029	Zucman-Rossi J	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.	Gastroenterology	2015	47
27213815	1029	Dauch D	A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.	Nature medicine	2016	15
21038412	1050	Zeng C	A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma.	Hepatology	2010	41
11752579	1316	Narla G	KLF6, a candidate tumor suppressor gene mutated in prostate cancer.	Science	2001	120
15480989	1499	Merle P	Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma.	Gastroenterology	2004	72
16964294	1499	Zucman-Rossi J	Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.	Oncogene	2007	59
17187432	1499	Boyault S	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.	Hepatology	2007	191
17295177	1499	Villanueva A	Genomics and signaling pathways in hepatocellular carcinoma.	Seminars in liver disease	2007	150
17785413	1499	Tward AD	Distinct pathways of genomic progression to benign and malignant tumors of the liver.	Proceedings of the National Academy of Sciences of the United States of America	2007	64
19723656	1499	Hoshida Y	Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.	Cancer research	2009	176
21324318	1499	Toffanin S	MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.	Gastroenterology	2011	53
21966251	1499	Nishida N	Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review.	Current genomics	2011	40
23463346	1499	Beyoğlu D	Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.	Hepatology	2013	37
23788652	1499	Kan Z	Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.	Genome research	2013	95
23887712	1499	Nault JC	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.	Nature communications	2013	82
25248380	1499	Friemel J	Intratumor heterogeneity in hepatocellular carcinoma.	Clinical cancer research 	2015	28
17283074	1956	Hsu SC	Characterization of a novel tripartite nuclear localization sequence in the EGFR family.	The Journal of biological chemistry	2007	83
19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
20022809	1956	Mitsudomi T	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.	The Lancet. Oncology	2010	783
20940188	1956	Sequist LV	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology 	2010	100
22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
24384534	1956	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology and therapeutics	2014	31
24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
24687833	1956	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	99
24919569	1956	Van Cutsem E	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clinical cancer research 	2014	22
25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
26530965	2064	Murtaza M	Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.	Nature communications	2015	33
24217577	2099	Merenbakh-Lamin K	D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.	Cancer research	2013	56
26261103	2099	Chu D	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.	Clinical cancer research 	2016	22
26829318	2184	Yin H	Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo.	Nature biotechnology	2016	43
23598278	2305	Kong X	Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.	Cancer research	2013	31
18929564	2475	Villanueva A	Pivotal role of mTOR signaling in hepatocellular carcinoma.	Gastroenterology	2008	182
25123086	2719	Nault JC	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.	Hepatology	2014	37
25807286	2778	Gudbjartsson DF	Large-scale whole-genome sequencing of the Icelandic population.	Nature genetics	2015	98
20959817	2875	Yin J	Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma.	The American journal of gastroenterology	2011	38
26752112	3052	Xue R	Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma.	Gastroenterology	2016	13
19318488	3082	Eder JP	Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.	Clinical cancer research 	2009	133
19440305	3172	Yuan X	Identification of an endogenous ligand bound to a native orphan nuclear receptor.	PloS one	2009	67
25557953	3337	Cornella H	Unique genomic profile of fibrolamellar hepatocellular carcinoma.	Gastroenterology	2015	17
19378339	3417	Kang MR	Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.	International journal of cancer	2009	86
22180306	3417	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	126
25369307	3417	Rizvi S	Cholangiocarcinoma: molecular pathways and therapeutic opportunities.	Seminars in liver disease	2014	27
26332546	3717	Baerlocher GM	Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.	The New England journal of medicine	2015	16
27011036	3815	Boikos SA	Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.	JAMA oncology	2016	15
19056857	3845	Santini D	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.	The oncologist	2008	57
21228335	3845	Bokemeyer C	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Annals of oncology 	2011	163
21239505	3845	Tie J	KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.	Clinical cancer research 	2011	47
21364579	3845	Knijn N	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.	British journal of cancer	2011	63
22266220	3845	O'Dell MR	Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.	Cancer research	2012	33
23200175	3845	Jänne PA	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.	The Lancet. Oncology	2013	153
23295441	3845	Sia D	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.	Gastroenterology	2013	61
24018645	3845	Vauthey JN	RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.	Annals of surgery	2013	29
25706875	3845	Matano M	Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.	Nature medicine	2015	74
25477334	4193	Meng X	MDM2-p53 pathway in hepatocellular carcinoma.	Cancer research	2014	23
19822006	4595	Half E	Familial adenomatous polyposis.	Orphanet journal of rare diseases	2009	81
19967722	4780	Kim YR	Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.	The Journal of pathology	2010	86
20019356	4780	Klaunig JE	Oxidative stress and oxidative damage in carcinogenesis.	Toxicologic pathology	2010	157
23325555	5265	Choi SM	Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells.	Hepatology	2013	51
20813970	5290	Esteva FJ	PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.	The American journal of pathology	2010	94
21594665	5290	Razis E	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.	Breast cancer research and treatment	2011	67
23248156	5290	Janku F	PIK3CA mutations in advanced cancers: characteristics and outcomes.	Oncotarget	2012	30
23670029	5728	Said R	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.	Oncotarget	2013	27
17538171	6390	Timmers HJ	Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.	Journal of clinical oncology 	2007	59
9988270	6714	Irby RB	Activating SRC mutation in a subset of advanced human colon cancers.	Nature genetics	1999	107
21690253	6774	Pilati C	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.	The Journal of experimental medicine	2011	58
23348506	7015	Huang FW	Highly recurrent TERT promoter mutations in human melanoma.	Science	2013	346
1672732	7157	Bressac B	Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.	Nature	1991	191
1849234	7157	Hsu IC	Mutational hotspot in the p53 gene in human hepatocellular carcinomas.	Nature	1991	202
1905840	7157	Hollstein M	p53 mutations in human cancers.	Science	1991	1290
10623654	7157	Vona G	Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells.	The American journal of pathology	2000	212
10700176	8312	Satoh S	AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.	Nature genetics	2000	215
18395098	8647	Strautnieks SS	Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families.	Gastroenterology	2008	59
21397858	9965	Sawey ET	Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.	Cancer cell	2011	75
17889654	10413	Dong J	Elucidation of a universal size-control mechanism in Drosophila and mammals.	Cell	2007	582
16618406	11186	Calvisi DF	Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.	Gastroenterology	2006	150
22146883	23411	Chen HC	SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.	Annals of surgical oncology	2012	37
22553202	23411	Nin V	Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase.	The Journal of biological chemistry	2012	38
